Capital Raise?, page-60

For dec 17 qtr as we’ve not seen P&L or bs it’s hard to be sure but we know they are saying 22m on operating SCF and that Includes 41% they have no control over and shouldn’t be on books as cash as not readily convertible to cash for them.
I suspect what they are doing (which would be wrong If so)
Dr cash and cash equivalents 22m BS
Dr Expense 5.3
Crcash 5.3
Cr deferred revenue 22m

Then each monthtake 1/12 of every advance in deferred revenue for each month received - numbers will depend on when receipts came in the qtr but even if every dollar of 22m dec17 qtr came in on Oct 1 will be limited to 3 months revenue so 5.5m reclassified revenue from deferred. With growth profile would expect most to come r gently so would expect less than half of 5.5m
Dr deferred revenue
Cr revenue

This amortisationjnl from deferred to tenure should only be on acceptance though so would be a lot less